EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Gut microbiota and clinical response to immune checkpoint inhibitor therapy in patients with advanced cancer

John Wen-Cheng Chang, Jia-Juan Hsieh, Chih-Yu Tsai, Horng-Yih Chiu, Yu-Feng Lin, Chiao-En Wu, Yung-Chi Shen, Ming-Mo Hou, Chieh-Ying Chang, Jian-An Chen, Chyi-Liang Chen, Cheng-Tang Chiu und 2 weitere

Biomedical Journal · 2024-10 · 47 (5) · 100698

DOI: 10.1016/j.bj.2024.100698 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomedical Journal, 2024-10. Verfasst von John Wen-Cheng Chang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, T…. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Immune Checkpoint Inhibitors, Neoplasms. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: There is currently no well-accepted consensus on the association between gut microbiota and the response to treatment of immune checkpoint inhibitors (ICIs) in patients with advanced cancer. METHODS: Fecal samples were collected before ICI treatment. Gut microbiota was analyzed using 16 S ribosomal RNA sequencing. We investigated the relationship between the α-diversity of fecal microbiota and patients' clinical outcomes. Microbiota profiles from patients and healthy controls were determined. Pre-treatment serum was examined by cytokine array. RESULTS: We analyzed 74 patients, including 42 with melanoma, 8 with kidney cancer, 13 with lung cancer, and 11 with other cancers. Combination therapy of anti-PD1 and anti-CTLA-4 was used in 14 patients, and monotherapy in the rest. Clinical benefit was observed in 35 (47.3 %) cases, including 2 complete responses, 16 partial responses, and 17 stable diseases according to RECIST criteria. No significant difference in α-diversity was found between the benefiter and non-benefiter groups. However, patients with α-diversity within the range of our healthy control had a significantly longer median overall survival (18.9 months), compared to the abnormal group (8.2 months) (p = 0.041, hazard ratio = 0.546) for all patients. The microbiota composition of the benefiters was similar to that of healthy individuals. Furthermore, specific bacteria, such as Prevotella copri and Faecalibacterium prausnitzii, were associated with a favorable outcome. We also observed that serum IL-18 before treatment was significantly lower in the benefiters, compared to non-benefiters. CONCLUSIONS: The α-diversity of gut microbiota is positively correlated with more prolonged overall survival in cancer patients following ICI therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal MicrobiomeImmune Checkpoint InhibitorsNeoplasmsHumansMaleFemaleMiddle AgedAgedAdultFecesAged, 80 and overTreatment Outcome

Stichwörter der Autor:innen

Clinical responseGut microbiotaImmune checkpoint inhibitors

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan; Immuno-Oncology Center of Excellence, Chang Gung Memorial Hospi…
  • Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan.
  • School of Medicine, Chang Gung University College of Medicine, Taoyuan, Taiwan.
  • Immuno-Oncology Center of Excellence, Chang Gung Memorial Hospital, Taoyuan, Taiwan; Department of Nursing, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
  • Molecular Infectious Disease Research Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan; Department of Microbiology and Immunology, Chang Gung University College of Medicine, Taoyuan, Taiwan.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan; Chang Gung Microbiota Therapy Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan.

Zitieren

APA

Chang, J. W., Hsieh, J. J., Tsai, C. Y., Chiu, H. Y., Lin, Y. F., Wu, C. E., Shen, Y. C., Hou, M. M., Chang, C. Y., Chen, J. A., Chen, C. L., Chiu, C. T., Yeh, Y. M., & Chiu, C. H. (2024). Gut microbiota and clinical response to immune checkpoint inhibitor therapy in patients with advanced cancer. Biomedical Journal, 47(5), 100698. https://doi.org/10.1016/j.bj.2024.100698

Vancouver

Chang JW, Hsieh JJ, Tsai CY, Chiu HY, Lin YF, Wu CE, et al. Gut microbiota and clinical response to immune checkpoint inhibitor therapy in patients with advanced cancer. Biomedical Journal. 2024;47(5):100698. doi:10.1016/j.bj.2024.100698

BibTeX
@article{Chang2024,
  author = {Chang, John Wen-Cheng and Hsieh, Jia-Juan and Tsai, Chih-Yu and Chiu, Horng-Yih and Lin, Yu-Feng and Wu, Chiao-En and Shen, Yung-Chi and Hou, Ming-Mo and Chang, Chieh-Ying and Chen, Jian-An and Chen, Chyi-Liang and Chiu, Cheng-Tang and Yeh, Yuan-Ming and Chiu, Cheng-Hsun},
  title = {Gut microbiota and clinical response to immune checkpoint inhibitor therapy in patients with advanced cancer},
  journal = {Biomedical Journal},
  year = {2024},
  volume = {47},
  number = {5},
  pages = {100698},
  doi = {10.1016/j.bj.2024.100698}
}
Kostenlos starten →